Furthermore, the presence of CTLA-4/PD-1 double-positive T cells indicates a deeply exhausted phenotype in human tumors, suggesting that dual PD1/CTLA4 blockade may exhibit more immunostimulatory activity.356 Indeed, in 2015, this immunotherapeutic regimen was approved for the treatment of melanoma. This evidence concerns the gene CTLA4 and melanoma.